Atopic Dermatitis - KOL Insight

Table of Contents

Executive summary (9)

Future treatment paradigm for atopic dermatitis

Research objectives (1)

Current treatment strategies (43)

• Dupixent (dupilumab; Sanofi/Regeneron) (10)
  • Key insights summary (10)
• Adbry/Adtralza (tralokinumab; LEO Pharma) (11)
  • Key insights summary (11)
• Olumiant (baricitinib; Lilly/Incyte) (8)
  • Key insights summary (8)
• Cibinqo (abrocitinib; Pfizer) (8)
  • Key insights summary (8)
• Rinvoq (upadacitinib; AbbVie) (6)
  • Key insights summary (6)

Late-stage pipeline programmes (34)

• Lebrikizumab (Lilly/Almirall) (6)
  • Key insights summary (6)
• Nemolizumab (Galderma/Chugai/Maruho) (6)
  • Key insights summary (6)
• Etrasimod (Pfizer) (7)
  • Key insights summary (7)
• Ivarmacitinib (SHR 0302; Reistone Biopharma) (6)
  • Key insights summary (6)
• Rocatinlimab (Kyowa Kirin/Amgen) (9)
  • Key insights summary (9)

Earlier-stage developments and other factors impacting treatment (12)

• Experts are underwhelmed by B 244 as a potential therapy for atopic dermatitis (11)
  • KOLs regard lirentelimab as interesting but question whether mast cells and eosinophils play a central role in atopic dermatitis (3)
  • LP 0145 has potential but some experts believe bispecific inhibition or selecting IL22-expressing population may hold more benefit (1)
  • Microbiome involvement in preventing atopic dermatitis is a formidable goal; KOLs agree very limited progress being made (2)
  • New topical formulations will be welcomed in the US; European KOLs are sceptical that they will reach the European market due to high cost (3)

Appendix (4)

• KOL details (4)
  • US KOLs (1)
  • European KOLs (2)